DE60001835T2 - Mesalazine enthaltende pharmazeutische zusammensetzungen mit gesteuerte freisetzung - Google Patents

Mesalazine enthaltende pharmazeutische zusammensetzungen mit gesteuerte freisetzung

Info

Publication number
DE60001835T2
DE60001835T2 DE60001835T DE60001835T DE60001835T2 DE 60001835 T2 DE60001835 T2 DE 60001835T2 DE 60001835 T DE60001835 T DE 60001835T DE 60001835 T DE60001835 T DE 60001835T DE 60001835 T2 DE60001835 T2 DE 60001835T2
Authority
DE
Germany
Prior art keywords
pharmaceutical compositions
mesalazine
controlled release
containing pharmaceutical
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60001835T
Other languages
English (en)
Other versions
DE60001835D1 (de
Inventor
Roberto Villa
Massimo Pedrani
Mauro Ajani
Lorenzo Fossati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cosmo Technologies Ltd
Original Assignee
Cosmo SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11383159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60001835(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cosmo SpA filed Critical Cosmo SpA
Publication of DE60001835D1 publication Critical patent/DE60001835D1/de
Application granted granted Critical
Publication of DE60001835T2 publication Critical patent/DE60001835T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
DE60001835T 1999-06-14 2000-06-08 Mesalazine enthaltende pharmazeutische zusammensetzungen mit gesteuerte freisetzung Expired - Lifetime DE60001835T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999MI001316A ITMI991316A1 (it) 1999-06-14 1999-06-14 Composizioni farmaceutiche orali a rilascio modificato di mesalazina
PCT/EP2000/005321 WO2000076481A1 (en) 1999-06-14 2000-06-08 Mesalazine controlled release oral pharmaceutical compositions

Publications (2)

Publication Number Publication Date
DE60001835D1 DE60001835D1 (de) 2003-04-30
DE60001835T2 true DE60001835T2 (de) 2003-11-13

Family

ID=11383159

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60027608T Expired - Lifetime DE60027608T2 (de) 1999-06-14 2000-06-08 Mesalazine enthaltende pharmazeutische Zusammensetzungen mit gesteuerter Freisetzung
DE60001835T Expired - Lifetime DE60001835T2 (de) 1999-06-14 2000-06-08 Mesalazine enthaltende pharmazeutische zusammensetzungen mit gesteuerte freisetzung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60027608T Expired - Lifetime DE60027608T2 (de) 1999-06-14 2000-06-08 Mesalazine enthaltende pharmazeutische Zusammensetzungen mit gesteuerter Freisetzung

Country Status (18)

Country Link
US (1) US6773720B1 (de)
EP (2) EP1287822B1 (de)
JP (2) JP4727875B2 (de)
CN (2) CN1217665C (de)
AT (2) ATE235234T1 (de)
AU (1) AU5077200A (de)
CA (1) CA2377299C (de)
DE (2) DE60027608T2 (de)
DK (2) DK1198226T3 (de)
ES (2) ES2194732T3 (de)
HK (2) HK1046247B (de)
IT (1) ITMI991316A1 (de)
MX (1) MXPA01012888A (de)
NO (1) NO329402B1 (de)
PT (2) PT1198226E (de)
RU (1) RU2245148C2 (de)
TR (1) TR200200561T2 (de)
WO (1) WO2000076481A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1173695C (zh) 1999-06-14 2004-11-03 科斯默股份公司 控制释放与掩蔽味道的口服药物组合物
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
AR036797A1 (es) 2001-10-15 2004-10-06 Ferring Bv Un metodo para preparar una composicion farmaceutica que comprende acido 5-aminosalicilico para utilizar en el tratamiento de colitis ulcerosa y enfermedades de crohn
ITMI20012599A1 (it) * 2001-12-11 2003-06-11 Cosmo Spa Composizioni farmaceutiche per la somministrazione orale di eparina osuoi derivati, utili per la terapia di malattie infiammatorie dell'int
US9308220B2 (en) 2001-12-11 2016-04-12 Cosmo Technologies Limited Pharmaceutical compositions for the oral administration of heparin or derivatives thereof
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
FR2852843B1 (fr) * 2003-03-24 2008-05-23 Karim Ioualalen Systeme galenique permettant le masquage du gout
WO2004093883A2 (en) * 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
US7737133B2 (en) 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
GB0322848D0 (en) * 2003-09-30 2003-10-29 Alpharma Ltd Tetracycline controlled release pharmaceutical dosage form
WO2005065673A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Atomoxetine formulations
WO2005072113A2 (en) * 2004-01-20 2005-08-11 Harty Richard F Compositions and methods of treatment for inflammatory diseases
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
EP2046389A2 (de) 2006-07-19 2009-04-15 The Board of Regents of the University of Texas System Phospholipid-zubereitungen und 5-aminosalicylsäure enthaltende pharmazeutische mittel zur behandlung von entzündlicher darmkrankheit
CA2662428A1 (en) * 2006-09-13 2008-03-20 The Procter & Gamble Company Methods of treatment for ulcerative colitis
MX2009002786A (es) * 2006-09-13 2009-03-30 Procter & Gamble Metodos de tratamiento para colitis ulcerante que utiliza aminosalicilato.
ES2398254T3 (es) 2006-11-17 2013-03-14 Shire Development Inc. Método de tratamiento de la enfermedad intestinal inflamatoria
FR2913884A1 (fr) * 2007-03-21 2008-09-26 Oralance Pharma Sa Systeme galenique hydrophobe non ionisable
US20090028944A1 (en) * 2007-07-16 2009-01-29 Balaji Sathurappan Pharmaceutical compositions comprising mesalamine
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
US20090169622A1 (en) * 2007-12-27 2009-07-02 Roxane Laboratories, Inc. Delayed-release oral pharmaceutical composition for treatment of colonic disorders
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
WO2011045775A1 (en) * 2009-10-16 2011-04-21 Ranbaxy Laboratories Limited A delayed release pharmaceutical composition of mesalamine
IT1398643B1 (it) 2010-03-04 2013-03-08 Cosmo Technologies Ltd Composizione solida per la somministrazione orale di coloranti, e utilizzo diagnostico della stessa
EP2425826A1 (de) * 2010-09-01 2012-03-07 Disphar International B.V. Mesalazin-Tablette mit verbesserter Auflösung
IT1402047B1 (it) * 2010-10-19 2013-08-28 Cross Pharma Sa Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali
EP2468264A1 (de) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Orale pharmazeutische Tablette zur gesteuerten Abgabe von Mesalazin und Verfahren zu deren Erhalt
MX2013007884A (es) 2011-01-07 2013-09-13 Elcelyx Therapeutics Inc Terapias a base de ligando del receptor quimiosensorial.
US9795792B2 (en) 2011-02-25 2017-10-24 Medtronic, Inc. Emergency mode switching for non-pacing modes
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
CN104254325A (zh) 2012-01-06 2014-12-31 埃尔舍利克斯治疗公司 双胍组合物和治疗代谢性病症的方法
EP2800562A2 (de) 2012-01-06 2014-11-12 Elcelyx Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von stoffwechselstörungen
US10071058B2 (en) * 2012-03-07 2018-09-11 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
US20150164920A1 (en) 2012-03-30 2015-06-18 Laboratorios Del Dr. Esteve S.A. Controlled release formulation comprising mesalamine
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
AU2013290100A1 (en) 2012-07-11 2015-01-29 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
EP2722058A1 (de) 2012-10-19 2014-04-23 Cosmo Technologies Ltd Orale Feststoffzusammensetzung mit Farbstoffen für die Verwendung bei der endoskopischen Diagnose
MX2020011594A (es) 2013-01-05 2022-01-13 Anji Pharma Us Llc Composición de liberación demorada que comprende biguanida.
WO2014129568A1 (ja) * 2013-02-22 2014-08-28 ゼリア新薬工業株式会社 腸溶錠
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
AU2014239683B2 (en) 2013-03-15 2018-05-17 Allergan Pharmaceuticals International Limited Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability
CN104922090B (zh) * 2015-07-03 2017-11-14 湖南方盛制药股份有限公司 美沙拉秦肠溶缓释微丸
EP3162362A1 (de) 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
ITUA20162293A1 (it) 2016-04-05 2017-10-05 Sofar Spa Processo per formulazioni solide di mesalazina
BR112019010691A2 (pt) 2016-11-28 2019-10-01 Cosmo Technologies Ltd composição oral sólida contendo corantes
US10098898B1 (en) 2017-12-04 2018-10-16 Handa Pharmaceuticals, Llc Release stable mesalamine dosage forms
EP3501503A1 (de) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Feste verabreichungszusammensetzung
EP3662895A1 (de) 2018-12-07 2020-06-10 Tillotts Pharma AG Verfahren zur herstellung von reduzierenden zuckerfreien 5-asa-tablettenkernen
IT201800011120A1 (it) 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide per la somministrazione di mesalazina o suoi derivati
CN112587506A (zh) * 2020-12-09 2021-04-02 南京森博医药研发有限公司 一种用于制备美沙拉嗪肠溶缓释胶囊的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921757A (en) * 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
JPS6248618A (ja) * 1985-08-27 1987-03-03 Zeria Shinyaku Kogyo Kk 徐放性製剤およびその製造法
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
IL92343A0 (en) * 1988-12-20 1990-07-26 Gist Brocades Nv Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them
IL92344A0 (en) * 1989-01-04 1990-07-26 Gist Brocades Nv Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules
JPH02282323A (ja) * 1989-04-21 1990-11-19 Shin Etsu Chem Co Ltd 徐放性錠剤の製造方法
JPH03232814A (ja) * 1990-02-08 1991-10-16 Shin Etsu Chem Co Ltd 徐放性錠剤の製造方法
IE61651B1 (en) 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
JP3011752B2 (ja) * 1990-10-23 2000-02-21 フロイント産業株式会社 徐放性製剤およびその製造方法
JP2829794B2 (ja) * 1991-02-08 1998-12-02 エスエス製薬 株式会社 徐放性経口投与型プラノプロフェン製剤
GEP19971086B (en) * 1991-02-22 1997-12-02 Tillotts Pharma Ag Peroral Pharmaceutically Dispensed Form for Selective Introducing of the Medicine into the Intestine
JPH0624962A (ja) * 1992-07-09 1994-02-01 Green Cross Corp:The 腸溶徐放性製剤
WO1994008568A1 (en) * 1992-10-16 1994-04-28 Nippon Shinyaku Co., Ltd. Method of manufacturing wax matrices
US5911980A (en) * 1996-06-27 1999-06-15 Macrochem Corporation Lipophilic and amphiphilic or hydrophilic film-forming polymer compositions, and use thereof in topical agent delivery system and method of delivering agents to the skin
AU5775398A (en) * 1996-12-17 1998-07-15 Poli Industria Chimica S.P.A. Site-specific controlled release dosage formulation for mesalamine
US5851555A (en) * 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
CN1173695C (zh) * 1999-06-14 2004-11-03 科斯默股份公司 控制释放与掩蔽味道的口服药物组合物

Also Published As

Publication number Publication date
CN1217665C (zh) 2005-09-07
DE60001835D1 (de) 2003-04-30
HK1085669A1 (en) 2006-09-01
ITMI991316A1 (it) 2000-12-14
DE60027608T2 (de) 2007-04-26
JP2003501458A (ja) 2003-01-14
CN100448448C (zh) 2009-01-07
EP1287822A3 (de) 2003-03-19
EP1287822B1 (de) 2006-04-26
RU2245148C2 (ru) 2005-01-27
PT1287822E (pt) 2006-07-31
ITMI991316A0 (it) 1999-06-14
CA2377299A1 (en) 2000-12-21
CN1720919A (zh) 2006-01-18
HK1046247A1 (en) 2003-01-03
TR200200561T2 (tr) 2002-06-21
HK1046247B (zh) 2006-04-07
EP1198226B1 (de) 2003-03-26
ATE324104T1 (de) 2006-05-15
JP5235839B2 (ja) 2013-07-10
DE60027608D1 (de) 2006-06-01
ATE235234T1 (de) 2003-04-15
US6773720B1 (en) 2004-08-10
ES2262749T3 (es) 2006-12-01
NO329402B1 (no) 2010-10-11
AU5077200A (en) 2001-01-02
NO20016107L (no) 2002-02-11
NO20016107D0 (no) 2001-12-14
DK1287822T3 (da) 2006-08-28
CA2377299C (en) 2009-05-12
EP1287822A2 (de) 2003-03-05
CN1355694A (zh) 2002-06-26
JP2010024241A (ja) 2010-02-04
MXPA01012888A (es) 2002-07-30
WO2000076481A1 (en) 2000-12-21
PT1198226E (pt) 2003-07-31
JP4727875B2 (ja) 2011-07-20
EP1198226A1 (de) 2002-04-24
DK1198226T3 (da) 2003-07-21
ES2194732T3 (es) 2003-12-01

Similar Documents

Publication Publication Date Title
ATE324104T1 (de) Mesalazine enthaltende pharmazeutische zusammensetzungen mit gesteuerter freisetzung
CA2158630A1 (en) Dosage forms containing thioctic acid or solid salts of thioctic acid with improved release and bioavailability
DE68909772T2 (de) Diclofenac-Natrium-Arzneizubereitung mit verlängerter Wirkstoffabgabe.
HK1068282A1 (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for usein treatment of ulcerative colitis and crohn's di sease
DE60211464D1 (de) Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung
DE68902531D1 (de) Dispergierbare zubereitung.
DE59907481D1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
IT1284604B1 (it) Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva
DE69831940D1 (de) Tablette mit verlängerter Wirkstoffabgabe im Magen
DE69710121T2 (de) Pharmazeutische Zusammensetzung aus stabilisierten lipophilen Matrizen mit kontrollierter Wirkstofffreisetzung
ES2194793T3 (es) Microcapsulas para la liberacion prolongada de farmacos.
DE60029946D1 (de) Arzneimittel gegen glomerulosclerose
ITMI20000972A0 (it) Formulazioni farmaceutiche, a rilascio modificato, con elevata biodisponibilita', contenenti principi attivi ad attivita' antibiotica.
IT8922398A0 (it) Composizioni farmaceutiche ad elevato assorbimento e stabilita', comprendente una calcitonina come sostanza attiva.
CO4910116A1 (es) Formulacion de liberacion controlada para farmacos basicos escasamente solubles
DE60115450D1 (de) Pirlindolhydrochlorid-Matrixformulierungen mit verlängerter Wirkstofffreigabe
PA8531801A1 (es) Formulaciones estabilizadas que comprenden composiciones hidroliticamente inestables

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: COSMO S.P.A., LAINATE, MILANO, IT

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: COSMO TECHNOLOGIES LIMITED, BRAY, WICKLOW, IE